RT @krychtiukmd: Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Card…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @MAROSFO: Efectos de Alirocumab sobre Lp(a) tras SCA. Reducciones de Lp(a) con alirocumab reducen el riesgo CV independientemente del cL…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @krychtiukmd: Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Card…
RT @krychtiukmd: Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Card…
RT @MAROSFO: Efectos de Alirocumab sobre Lp(a) tras SCA. Reducciones de Lp(a) con alirocumab reducen el riesgo CV independientemente del cL…
RT @MAROSFO: Efectos de Alirocumab sobre Lp(a) tras SCA. Reducciones de Lp(a) con alirocumab reducen el riesgo CV independientemente del cL…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @MAROSFO: Efectos de Alirocumab sobre Lp(a) tras SCA. Reducciones de Lp(a) con alirocumab reducen el riesgo CV independientemente del cL…
RT @krychtiukmd: Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Card…
RT @krychtiukmd: Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Card…
RT @MAROSFO: Efectos de Alirocumab sobre Lp(a) tras SCA. Reducciones de Lp(a) con alirocumab reducen el riesgo CV independientemente del cL…
RT @krychtiukmd: Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Card…
Efectos de Alirocumab sobre Lp(a) tras SCA. Reducciones de Lp(a) con alirocumab reducen el riesgo CV independientemente del cLDL, nuevo objetivo de tratamiento? @JTLLERGO @PacoFuentes5 @R_Campuzano_R @acorderofort https://t.co/ROuuyI6TRK
RT @krychtiukmd: Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Card…
Lp(a) lowering via alirocumab is an independent contributor to MACE reduction after ACS - in the new @JACCJournals #Cardiotwitter #CardioEd @PCSK9Forum @lipoproteinaFDN https://t.co/AhviaWyLov https://t.co/ZU5Z3q8WBU
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
RT @Lpa_Doc: The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is a…
The Lp(a) ODYSSEY Outcomes paper is now out: https://t.co/HGaHuPkgqN. It concludes "Lipoprotein(a) lowering by alirocumab is an independent contributor to MACE reduction". Every 10 mg/dL reduction in Lp(a) was associated with 6% RRR.
Every 1-mg/dl ↓ in Lp(a) with alirocumab associated with a HR of 0.994 (p = 0.0081) https://t.co/BHPu3RWsX2 @JACCJournals https://t.co/BmUv5z1kbr
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome | JACC: Journal of the American College of Cardiology https://t.co/PXevawShVC
RT @gabrielsteg: Lp(a) reduction by Alirocumab was an independent contributor to event reduction after ACS in ODYSSEY OUTCOMES. https://t.…
Lp(a) reduction by Alirocumab was an independent contributor to event reduction after ACS in ODYSSEY OUTCOMES. https://t.co/YeW5w223Lw